These findings suggest that binding-defective CRLF1 variants have the potential to serve as tumor-specific polypeptide drugs, enhancing chemotherapy effectiveness as adjuvant therapy in ovarian cancer (Fig. 8H). The gene discussed is CRLF1; the disease is ovarian cancer.